GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (XPAR:ALBPS) » Definitions » Short Percentage of Float

Biophytis (XPAR:ALBPS) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Biophytis Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Biophytis's Short Percentage of Float

For the Biotechnology subindustry, Biophytis's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biophytis's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Biophytis's Short Percentage of Float falls into.


Biophytis (XPAR:ALBPS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biophytis SA (XPAR:ALBPS) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALVET XPAR:ALMDP XPAR:ALQGC XPAR:ALTME XPAR:ALINT XPAR:ALPAT XPAR:ALTHX XPAR:ALNFL XPAR:ALNEV XPAR:ALPHA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BPTS:USA 6XB:Germany
Address
BC 9, Batiment A 4eme etage, 4 pace Jussieu, Sorbonne University, Paris, FRA, 75005
Website
https://www.biophytis.com
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

Biophytis (XPAR:ALBPS) Headlines

No Headlines